Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:30 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,319 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma
Interventions
JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more
Conditions
Opioid-use Disorder, Substance Use Disorders, Parenting
Interventions
pCARE, Standard Early Intervention services
Behavioral · Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Springfield, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Alcohol Inhibits Drug Metabolism by Carboxylesterases

NCT01708369
Conditions
Drug Interactions
Interventions
Placebo, Ethanol, Oseltamivir, Aspirin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
Interventions
NT-175
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Liver Cancer
Interventions
Lipiodol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions
ONC201, Radiation Therapy, Paxalisib, DNX-2401
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Conditions
Pancreatic Neuroendocrine Cancer
Interventions
MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Viral Infections, Bone Marrow Transplant Infection
Interventions
Virus Specific T cells (VSTs)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Prostate Cancer
Interventions
EC1169, EC0652
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more
Conditions
Lung Cancer, Lung Metastases
Interventions
VGT-309
Drug
Lead sponsor
Vergent Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Duarte, California • Orlando, Florida • Rochester, Minnesota + 2 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adaptive Preventive Intervention for College Alcohol Use

NCT03930524
Conditions
College Student Drinking
Interventions
Personalized Normative Feedback (PNF), Self-Monitoring (SM), Web-BASICS, Health Promotion Consultation, M-Bridge Online Health Coach
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 21 Years
Enrollment
891 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Results available

WeChat Quit Coach Pilot Study

NCT05130788
Conditions
Smoking Cessation
Interventions
WeChat Quit Coach, Leaflet, Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges
Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions
[68Ga]Ga-ABY-025
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Acute Pain, Headache, Musculoskeletal Pain
Interventions
Usual Care/Guideline, Opioid Justification, Provider Comparison
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
22,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Glioblastoma (GBM), Brain Metastasases
Interventions
Risvutatug rezetecan
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions
27T51, Cemiplimab, Bevacizumab
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more
Conditions
Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
Interventions
MET/CBT based individualized counseling, Buprenorphine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMT-162
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more
Conditions
Metastatic Pancreatic Cancer
Interventions
XNW28012
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Detroit, Michigan • Grand Rapids, Michigan • Lake Success, New York + 5 more
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions
Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone
Procedure · Drug · Radiation + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
Hypertrophic Scar
Interventions
STP705, Placebo
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California